Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $195.92.
ASND has been the subject of several recent analyst reports. Bank of America raised their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. Jefferies Financial Group raised their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. JPMorgan Chase & Co. dropped their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, September 16th.
Read Our Latest Report on ASND
Institutional Inflows and Outflows
Ascendis Pharma A/S Stock Down 3.1 %
Shares of NASDAQ:ASND opened at $122.80 on Friday. The company has a market capitalization of $7.15 billion, a price-to-earnings ratio of -12.78 and a beta of 0.64. The company has a 50 day moving average of $134.04 and a two-hundred day moving average of $133.89. Ascendis Pharma A/S has a 52-week low of $86.54 and a 52-week high of $161.00.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. On average, equities analysts anticipate that Ascendis Pharma A/S will post -7.2 earnings per share for the current year.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Featured Stories
- Five stocks we like better than Ascendis Pharma A/S
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- CD Calculator: Certificate of Deposit Calculator
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.